Pomegra
Zimmer Biomet Stock Jumps 13% After Q3 Earnings Beat
Why is Zimmer Biomet stock up today?
Zimmer Biomet (ZBH) stock jumped about 13% to $109.66 on Wednesday after an earnings beat, as the company raised its 2026 profit forecast to $8.50–$8.60 a share.
Key numbers
| Q3 net sales | $2.063B+3.1% YoY (+3.7% constant currency) |
|---|---|
| Q3 adjusted EPS | $1.90$0.02 above $1.88 consensus |
| 2026 adjusted EPS guidance | $8.50–$8.60from $8.47–$8.59 |
| Hip sales | $536.5M+7.0% constant currency |
| Knee sales | $767.5M-2.6% constant currency |
| Share price move | $109.66+13% (about +15% at 11:02 ET per MarketBeat; one early report showed +1.5%) |
What happened
Zimmer Biomet (ZBH) stock jumped about 13% to $109.66 on Wednesday after an earnings beat, as the company raised its 2026 profit forecast to $8.50–$8.60 a share. Sales for the three months to September were $2.06 billion, up 3.1% from a year ago. Profit per share, adjusted to leave out one-off items, was $1.90, two cents above what analysts expected. Hip sales grew 7.0%, while knee sales fell 2.6%. The company also nudged up its yearly sales-growth forecast (guidance).
Why it matters
Zimmer Biomet makes knee and hip replacements, a business investors have worried is slowing. Last week Stryker, a bigger rival, fell sharply after saying the hip and knee market cooled more than expected. Smith+Nephew also cut its 2026 profit forecast. Zimmer Biomet's raised outlook suggests it is holding up better than some rivals, which is why the shares moved so much.
Who this affects
- MarketbullishLow impact
- Healthcare investors get a positive signal on joint-implant demand.
- CompanybullishHigh impact
- Shareholders gain; shares jumped about 13% on the results.
- CompetitorsmixedMedium impact
- Stryker and Smith+Nephew face a softer hip and knee market.
- IndustrymixedMedium impact
- Hip demand looks firm, but knee sales and market growth remain uneven.
Zimmer Biomet vs Stryker, Smith+Nephew
How we got here
Stryker reports Q3; shares fall about 12% after hours on slower hip and knee market.
Zimmer Biomet reports Q3 sales of $2.063B and raises 2026 adjusted EPS outlook.
Smith+Nephew trims its 2026 profit forecast, citing a softer US joint-replacement market.
Zimmer Biomet shares jump about 13% to $109.66 in Wednesday trading.
What to watch
- Whether knee sales return to growth after falling 2.6% in Q3.Q4 2026
- Zimmer Biomet's next results and whether it keeps its raised $8.50–$8.60 profit outlook.Q1 2027
- Further signs of hip and knee market softness from rivals Stryker and Smith+Nephew.Q4 2026
Educational content only. Not investment advice.
More briefsAll briefs →
Wayfair Stock Jumps 10% After Q3 Earnings Beat
Wayfair (W) beat profit forecasts with $0.93 per share and sales up 9.7% to $3.42B as shoppers bought more.
Russia-Ukraine Talks Set for Abu Dhabi as Strike Kills 37
US envoy Witkoff set Nov. 10–11 talks as the Zaporizhzhia strike toll rose from 31 to 37, with 59 missing
Duolingo Stock Jumps 12% After Earnings Beat, Raised Outlook
Duolingo (DUOL) posted $309M in revenue and 64.9M daily users, up 29%, and lifted its 2026 forecast.